Piper Sandler’s 2025 biopharma outlook paints a mixed picture, with the firm noting some upside opportunities despite persistent macroeconomic challenges ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE